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Abstract: The synthesis of 3-substituted L-fuco-azafagomines from
D-lyxose is reported. They represent the first example of aza-C-gly-
cosides having a biimino (–NH–NH–) moiety. The key step of the
synthesis is the introduction of the hydrazine moiety by reductive
hydrazination of a 1-deoxy-ketohexose with tert-butyl carbazate.
Their glycosidase inhibitory properties are also reported.
Key words: azasugars, glycosidases, fucosidase inhibitors, aza-
fagomines, C-glycosides
a-L-Fucosidase is an exoglycosidase involved in the trim-
ming of nonreducing terminal L-fucose units during the
biosynthetic processing of fucose-containing glycoconju-
gates.1 This enzyme, in common with other glycosidases,
has glycosyl transfer activity and, therefore, can be also
used in the synthesis of fucosyl glycans.2 a-L-Fucosidase
is associated with a great variety of physiological and
pathological events. For example, aberrant distribution of
fucose on fucose-containing glycoconjugates is found in
inflammation processes, cancer, and cystic fibrosis.3 In-
hibitors of a-L-fucosidase can provide useful information
about the functions of the enzyme and the basis for the de-
velopment of potential therapeutic agents.4
Among the most powerful a-L-fucosidase inhibitors are L-
fuco hydroxylated piperidines such as L-fuconojirimycin
(FNJ, 1),5 although the intrinsic instability caused by the
lability of the N,O-acetal function prevents its biological
use. The 1-hydroxymethyl-FNJ6 and 1-aminomethyl-
FNJ,7 which have a C–C bond at C-1, are stable C-glyco-
syl analogues8 that have been used to generate potent in-
hibitors of a-L-fucosidases.9
On the other hand, Bols and co-workers have described
the preparation of (3S,4R,5S)-3-methylhexahydropy-
ridazine-4,5-diol (2), the so-called ‘fuco-azafagomine’
(Figure 1) that showed interesting inhibitory properties.10
To the best of our knowledge, 2 is the only reported exam-
ple of a L-fuco polyhydroxylated hexahydropyridazine.
We report herein for the first time the synthesis and the
glycosidase inhibitory properties of the C-3 substituted
fuco-azafagomines 3a and 3b. Both compounds can be
used as new leads in the search for selective and potent in-
hibitors of a-L-fucosidases. The hydroxylated L-fuco-
hexahydropyridazine moiety can be used as core structure
to mimic the fucosyl cation generated in the enzymatic
hydrolysis. Besides, the hydroxymethyl or aminomethyl
groups at C-3 can be further functionalized giving a li-
brary of derivatives by a diversity-oriented synthesis.
These compounds could contribute to a better understand-
ing of the inhibition mechanisms of fucosidases in terms
of structural and conformational changes, charge disloca-
tion, and protonation as it has been made with azafago-
mine analogues in glucosidases.11
The retrosynthetic analysis for the preparation of com-
pounds 3a and 3b is indicated in Scheme 1. The key steps
imply cyclization of 2-methyl glycosylhydrazines, which
were obtained by reductive hydrazination of a 1-deoxyke-
tohexose easily prepared from D-lyxose, which contains
the correct configuration at C-4 and C-5 of our target com-
pounds.
Scheme 1
Thus, starting from D-lyxose, tri-O-protected D-lyxono-
lactone 5 could be easily obtained following a similar pro-
cedure to that described in the literature12 (Scheme 2).
Addition of MeLi13 afforded the protected 1-deoxy-keto-
hexose 6 as a 3:1 mixture of anomers. Reductive hydrazi-
nation of 6 using tert-butyl carbazate, NaBH3CN, and
acetic acid in MeOH at 65 °C afforded the mixture of hy-
drazines 7 in 82% yield. Reaction of 7 with benzyl chlo-
roformate, followed by mesylation and selective Boc
deprotection gave crude monohydrazides that were treat-
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ed with Et3N in MeOH at reflux to afford cyclic deriva-
tives 8 and 9 as a 2.1:1 mixture of diastereomers. This
sequence could be efficiently carried out without interme-
diate purification, affording the corresponding hexa-
hydropyridazines in 71% overall yield after
chromatographic separation.
Scheme 2
Compounds 8 and 9 were fully characterized by their
spectroscopic data14 but the configuration of C-6 was dif-
ficult to assign. Fortunately, deprotection of 8 followed by
tosylation afforded crystalline tosyl derivative 10, the
structure of which was unambiguously confirmed by X-
ray crystallography (Figure 2).15 The 1H NMR spectrum
of 9 showed a large coupling constant (J = 9.3 Hz) be-
tween H-3 and H-4 and no coupling constant between H-
5 and H-6. These results together with a coupling constant
of 5.0 Hz between H-4 and H-5 indicated that 9 had a chair
conformation with the C-3 substituent in equatorial and
the Me-6 in axial positions. However, although the X-ray
structure of 10 indicated a chair conformation, its 1H
NMR spectrum16 showed coupling constant values of 4.5,
5.5 and 5.5 Hz for J3,4, J4,5, and J5,6, respectively. These
values were also observed for compound 8, which indi-
cates that a conformational equilibrium for both deriva-
tives takes place in solution.
Reaction of 10 with TBAN3 followed by reduction of the
azido group with H2S afforded protected aminomethyl de-
rivative 11.
Figure 2 X-ray crystallographic structure for compound 10
Hydrogenation of compound 8 afforded hydrazone 12 in
good yield. The formation of this product can be ex-
plained by oxidation of the hydrazine to the corresponding
azo compound, followed by isomerization of the double
bond to the more stable hydrazone.17 Then, deprotection
of compounds 8 and 9 was attempted by treatment with
TBAF, followed by acidic removal of the acetonide af-
fording N-protected alcohols 13 and 14 in good to excel-
lent yields. Final hydrogenation of these compounds
under acidic conditions afforded desired hydroxylated
hexahydropyridazines 3a and 15,18 in quantitative yields
as the corresponding hydrochloride salts. Acidic treat-
ment of 11 and subsequent catalytic hydrogenation fur-
nished compound 3b as hydrochloride salt in excellent
overall yield (Scheme 3). Hydrogenation under acidic
conditions is critical to avoid undesired oxidation.
Derivatives 3a, 3b, and 15 have been analyzed for their in-
hibitory activities towards twelve commercially available
glycosidases (Table 1).19 Compound 3a was a selective
and competitive inhibitor of a-L-fucosidase from bovine
kidney (97% at 1 mM concentration, Ki = 4.2 mM) which
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is a comparable value to that reported for fuco-azafagom-
ine 2,10 showing that the C-3 substituent is not detrimental
for the inhibition. It is worth noting that compound 3a did
not inhibit any of the other enzymes assayed: a-galactosi-
dases from coffee beans, b-galactosidases from Escheri-
chia coli and Aspergillus orizae, a-glucosidases from
yeast and from rice, amyloglucosidase from Aspergillus
niger, b-glucosidases from almonds, a-mannosidases
from Jack beans, b-mannosidases from snail, b-xylosidas-
es from Aspergillus niger, and b-N-acetylglucosaminidas-
es from Jack beans. Compounds 3b and 15 are much
weaker inhibitors of a-L-fucosidases from bovine kidney
(44% for 3b and 17% for 15, at 1 mM concentration) and
did not inhibit the other enzymes. Compound 15, epimer
of 3a at C-6, showed a weak inhibition towards a-L-fu-
cosidases indicating the importance of the S configuration
at Me-6 to bind the enzyme.
In summary, the synthesis of new C-3-substituted fuco-
configurated hydroxylated hexahydropyridazines from D-
lyxose is reported. They can be considered as the first ex-
amples of aza-C-glycosides having a biimino (–NH–NH–)
moiety and constitute interesting lead compounds for the
search of new a-L-fucosidase inhibitors. In spite of that
compound 3b is a weak inhibitor of a-L-fucosidases, its
triamino functionality makes it a promising candidate for
the discovery of fucosidase inhibitors by combinatorial
procedures through the approach of dynamic libraries of
imines20 or through the in situ evaluation of libraries of
amides.7
The use of lead compounds 3a and 3b in the synthesis of
new derivatives, the conformational analysis and the cor-
responding biological studies are currently in progress in
our laboratory and will be reported in due course.
Acknowledgment
We thank the Ministerio de Ciencia e Innovación of Spain
(CTQ2008-01565/BQU) and the Junta de Andalucía (FQM-345 and
P07-FQM-03056) for financial support. We also thank CITIUS of
the University of Seville. E.M.C. thanks the Ministerio de Educa-
ción for a FPU fellowship.
References and Notes
(1) (a) Ma, B.; Simala-Grant, J. L.; Taylor, D. E. Glycobiology 
2006, 16, 158R. (b) Vocadlo, D.; Davies, G. J. Curr. Opin. 
Chem. Biol. 2008, 12, 539. (c) Davies, G. J.; Ducros, V. 
M.-A.; Varrot, A.; Zechel, D. L. Biochem. Soc. Trans. 2003, 
31, 523. (d) Benesova, E.; Markova, M.; Lipovova, P.; 
Kralova, B. Chem. Listy 2005, 99, 324.
(2) (a) Berteau, O.; Bielicki, J.; Kilonda, A.; Delphine Machy, 
D.; Anson, D. S.; Kenne, L. Biochemistry 2004, 43, 7881. 
(b) Osanjo, G.; Dion, M.; Drone, J.; Solleux, C.; Tran, V.; 
Rabiller, C.; Tellier, C. Biochemistry 2007, 46, 1022.
(3) (a) Becker, D. J.; Lowe, J. B. Glycobiology 2003, 13, 41R. 
(b) Compain, P.; Martin, O. R. Bioorg. Med. Chem. 2001, 9, 
3077. (c) Springer, T. A.; Lasky, L. A. Nature (London) 
1991, 349, 196. (d) Ayude, D.; Fernández-Rodríguez, J.; 
Rodríguez-Berrocal, F. J.; Martínez-Zorzano, V. S.; De 
Carlos, A.; Gil, E.; De la Cadena, M. P. Oncology 2000, 59, 
310. (e) Michalski, J. C.; Klein, A. Biochim. Biophys. Acta 
1999, 1455, 69. (f) Glick, M. C.; Kothari, V. A.; Liu, A.; 
Stoykova, L. I.; Scanlin, T. F. Biochimie 2001, 83, 743.
(4) (a) Kajimoto, T.; Node, M. Curr. Top. Med. Chem. 2009, 9, 
13. (b) D’Alonzo, D.; Guaragna, A.; Palumbo, G. Curr. 
Med. Chem. 2009, 16, 473. (c) Gerber-Lemaire, S.; 
Juillerat-Jeanneret, L. Mini-Rev. Med. Chem. 2006, 6, 1043. 
(d) Robina, I.; Moreno-Vargas, A. J.; Carmona, A. T.; 
Vogel, P. Curr. Drug Metabol. 2004, 5, 329.
(5) Dubernet, M.; Defoin, A.; Tarnus, C. Bioorg. Med. Chem. 
Lett. 2006, 61, 1172.
(6) (a) Fleet, G. W. J.; Namgoong, S. K.; Barker, C.; Baines, S.; 
Jacob, G. S.; Winchester, B. Tetrahedron Lett. 1989, 30, 
4439. (b) Andrews, D. M.; Bird, M. I.; Cunningham, M. M.; 
Ward, P. Bioorg. Med. Chem. Lett. 1993, 3, 2533. 
(c) Beacham, A. R.; Smelt, K. H.; Biggadike, K.; Britten, 
C. J.; Hackett, L.; Winchester, B. G.; Nash, R. J.; Griffiths, 
R. C.; Fleet, G. W. J. Tetrahedron Lett. 1998, 39, 151.
(7) Wu, C.-Y. i.; Chang, C.-F.; Chen, J. S.-Y.; Wong, C.-H.; 
Lin, C.-H. Angew. Chem. Int. Ed. 2003, 42, 4661.
(8) (a) Davis, B. G. Tetrahedron: Asymmetry 2009, 20, 645. 
(b) Iminosugars: From Synthesis to Therapeutic 
Applications; Compain, P.; Martin, O. R., Eds.; Wiley-VCH: 
Weinheim, 2007. (c) Robina, I.; Vogel, P. Synthesis 2005, 
675.
(9) (a) Ho, C.-W.; Lin, Y.-N.; Chang, C.-F.; Li, S.-T.; Wu, 
Y.-T.; Wu, C.-Y.; Chang, C.-F.; Liu, S.-W.; Li, Y.-K.; Lin, 
C.-H. Biochemistry 2006, 45, 5695. (b) Chang, C.-F.; Ho, 
C.-W.; Wu, C.-Y.; Chao, T.-A.; Wong, C.-H.; Lin, C.-H. 
Chem. Biol. 2004, 11, 1301.
(10) Jensen, H. H.; Jensen, A.; Hazzel, R. G.; Bols, M. J. Chem. 
Soc., Perkin Trans. 1 2002, 1190.
Scheme 3
8
9
NCbz
H
N
MeHO
OH
HO
NCbz
H
N
MeHO
OH
HO
1413
1. TBAF/THF
2. HCl–THF (1:1)
90% 83%
H
2
, Pd/C
MeOH, HCl
3a (HCl) 15(HCl)
N
H
N
MeO
O
TBDPSO
quant quant
H
2
, Pd/C
MeOH
73%
12
NH
N
HO
HO
H
Me
NH
N
HO
HO
H
Me
OH
OH
3b (2HCl)
NH
N
HO
HO
H
Me
NH
2
1. HCl–THF (1:1)
2. HCl, H
2
, Pd/C
11
94%
Table 1 Inhibitory Activities of 3-substituted L-fuco-azafago-
minesa–c
Compound a-L-Fucosidase (%)
3a 97 (Ki = 4.2 mM)
3b 44
15 17
a
 For measurement conditions, see ref. 19.
b
 The mode of inhibition for given Ki is competitive.
c
 Percentage of inhibition at 1 mM, Ki in mM, when measured. Optimal 
pH, 37 °C.
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6) ppm. MS–FAB: m/z (%) = 513 (100) [M + Na]+, 491 (10) 
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(17) This process of oxidation–isomerization has been previously 
studied for hydrazines and some examples are reported, see: 
Stone, K. J.; Greenberg, M. M.; Blackstock, S. C.; Berson, 
J. A. J. Am. Chem. Soc. 1989, 111, 3659; see also ref. 11a.
(18) Analytical Data for 3a
[a]D22 –44.6 (c 0.6, MeOH). 1H NMR (500 MHz, CD3OD): 
d = 3.85–3.82 (m, 2 H, H-5, H-1′a), 3.74 (dd, 1 H, 
2J1¢b,1¢a = 11.6 Hz, J1¢b,3 = 5.5 Hz, H-1′b), 3.63 (dd, 1 H, 
J4,3 = 10.3 Hz, J4,5 = 2.8 Hz, H-4), 3.35 (qd, 1 H, J6,Me-6 = 6.8 
Hz, J6,5 = 1.2 Hz, H-6), 3.24 (ddd, 1 H, J3,1¢a = 2.9 Hz, H-3), 
1.28 (d, 3 H, Me-6) ppm. 13C NMR (125.7 MHz, CD3OD): 
d = 69.6 (C-5), 68.1 (C-4), 60.1 (C-1′), 58.0 (C-6), 57.5 (C-
3), 14.0 (Me-6) ppm. MS (CI): m/z (%) = 163 (40) [M + H]+. 
HRMS (CI): m/z calcd for C6H15N2O3 [M + H]+: 163.1083; 
found: 163.1083.
Analytical Data for 15
[a]D22 –12.3 (c 0.85, MeOH). 1H NMR (500 MHz, CD3OD): 
d = 3.85 (dd, 1 H, 2J1¢a,1¢b = 11.5 Hz, J1¢a,3 = 3.7 Hz, H-1¢a), 
3.81 (dd, 1 H, J4,3 = 7.4 Hz, J4,5 = 2.9 Hz, H-4), 3.77 (dd, 1 
H, J1¢b,3 = 6.9 Hz, H-1¢b), 3.71 (m, 1 H, H-5), 3.51 (qd, 1 H, 
J6,Me-6 = 6.9 Hz, J6,5 = 5.4 Hz, H-6), 3.36 (td, 1 H, H-3), 1.34 
(d, 3 H, Me-6) ppm. 13C NMR (125.7 MHz, CD3OD): d = 
70.1 (C-5), 65.4 (C-4), 60.5 (C-3), 60.2 (C-1¢), 56.6 (C-6), 
13.2 (Me-6) ppm. MS (CI): m/z (%) = 163 (65) [M + H]+. 
HRMS (CI): m/z calcd for C6H15N2O3 [M + H]+: 163.1083; 
found: 163.1087.
(19) For the conditions used in the biological tests, see: (a) Saul, 
R.; Chambers, J. P.; Molyneux, R. J.; Elbein, A. D. Arch. 
Biochem. Biophys. 1983, 221, 593. (b) Brandi, A.; Cicchi, 
S.; Cordero, F. M.; Frignoli, R.; Goti, A.; Picasso, S.; Vogel, 
P. J. Org. Chem. 1995, 60, 6806.
(20) Gerber-Lemaire, S.; Popowycz, F.; Rodriguez-Garcia, E.; 
Carmona Asenjo, A. T.; Robina, I.; Vogel, P. 
ChemBioChem 2002, 3, 466.
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